News from sponsors
Opdivo is reimbursed as of 1st of January in Lung (NSCLC), RCC (renal) and Hodgkin in monotherapy, as well as in melanoma in combination with Yervoy.
More information can be read in the article of BMS (PDF)
The cancer immunity cycle: a framework for cancer immunotherapy
More information can be read in the article of Roche (PDF)